

**PALM INTRANET**Day : Wednesday  
Date: 12/10/2003  
Time: 09:46:38**Inventor Name Search Result**

Your Search was:

Last Name = NARKUNAN

First Name = KESAVARAM

Application#	Patent#	Status	Date Filed	Title	Inventor Name 2
<u>60421549</u>	Not Issued	020	10/25/2002	PROCESS FOR MAKING CAMPTOTHECIN DERIVATIVES	NARKUNAN, KESAVARAM
<u>10627444</u>	Not Issued	030	07/25/2003	PROCESS FOR MAKING CAMPTOTHECIN DERIVATIVES	NARKUNAN, KESAVARAM

**Inventor Search Completed: No Records to Display.**

	<b>Last Name</b>	<b>First Name</b>
<b>Search Another:</b>	<input type="text" value="Narkunan"/>	<input type="text" value="Kesavaram"/>
<b>Inventor</b>	<input type="button" value="Search"/>	

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

10/627,444

STN - structure search


12-10-03

=> d ibib abs hitstr 1-5

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2000:790315 CAPLUS  
 DOCUMENT NUMBER: 133:350387  
 TITLE: Synthesis of novel highly lipophilic camptothecin  
 analogs for use in treating cancers and leukemia  
 INVENTOR(S): Kochat, Harry; Chen, Xinghai; Huang, Qiuli;  
 Peddaiahari, Seetharamulu; Hausheer, Frederick H.  
 PATENT ASSIGNEE(S): Bionumerik Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 49 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066127	A1	20001109	WO 2000-US12318	20000504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-132414P P 19990504  
 OTHER SOURCE(S): MARPAT 133:350387  
 GI



AB This invention discloses the prepn. of novel analogs of camptothecin {I; R, R1 = H, alkyl, alkenyl, alkynyl, alkoxy, halo, aryl, arylalkyl, arylalkenyl, arylalkynyl, -X1-(alkylene, alkenylene, alkynylene)-SiR12R13R14 (R12 = R13 = R14 = H, alkyl), -X1-(alkylene, alkenylene, alkynylene, phenylene, benzylene)-NR9R10 (R9, R10 = H, alkyl or nitrogen protecting group), OR6 (R6 = H, alkyl or oxygen protecting group); R2 = R3 = R4 = R5 = H, alkyl, alkenyl, alkynyl, alkoxy, halo, aryl, arylalkyl, arylalkenyl, arylalkynyl, amino, protected amino, nitro, -X2-(alkylene, alkenylene, alkynylene)-SiR12R13R14, -X2-(alkylene, alkenylene, alkynylene, phenylene, benzylene)-NR9R10 [X1, X2 = individually S, NR15(R15 = H, alkyl, N-protecting group or absent)], or OR8 [R8 = H, alkyl or -(alkylene, alkenylene or alkynylene)-SiR12R13R14]; R7 = H, alkyl, aryl, -SiR12R13R14 or absent when R11 = H; R11 = H, CO, SO2, CS, SO, alkylene, O or S; X = CH2 or absent} or a pharmaceutically acceptable salt thereof. Thus, I (R = R2 = R3 = R4 = R5 = R7 = H, R1 = CH2CH2Si(Me)3, R11

10/627,444

= O, X = CH<sub>2</sub>) (II) was prepd. by the reaction of homocamptothecin I [R = R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = R<sub>5</sub> = R<sub>7</sub> = H, R<sub>11</sub> = O, X = CH<sub>2</sub>(III)] with 3-trimethylsilyl-propanal.

IT 305322-68-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)

(Synthesis of novel highly lipophilic camptothecin analogs for use in treating cancers and leukemia)

RN 305322-68-3 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, 6-oxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 276250-51-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)

(Synthesis of novel highly lipophilic camptothecin analogs for use in treating cancers and leukemia)

RN 276250-51-2 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4,9-dihydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 203923-89-1P

RL: BYP (Byproduct); RCT (Reactant); **PREP (Preparation)**; RACT

10/627,444


(Reactant or reagent)

(Synthesis of novel highly lipophilic camptothecin analogs for use in treating cancers and leukemia)

RN 203923-89-1 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,  
4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:754523 CAPLUS

DOCUMENT NUMBER: 133:322036

TITLE: Methods for preparation of camptothecin analogs having  
antitumor activity

INVENTOR(S): Curran, Dennis P.; Josien, Hubert; Bom, David; Burke,  
Thomas G.

PATENT ASSIGNEE(S): University of Pittsburgh, USA

SOURCE: U.S., 52 pp., Cont.-in-part of U.S. Ser. No. 921,102.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6136978	A	20001024	US 1998-212178	19981215
US 6150343	A	20001121	US 1997-921102	19970829
WO 2000035924	A1	20000622	WO 1999-US29937	19991215
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1140948	A1	20011010	EP 1999-965287	19991215
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002532505	T2	20021002	JP 2000-588183	19991215
US 2001029298	A1	20011011	US 2001-815459	20010323

10/627,444

US 6620937	B2	20030916		
US 2002193598	A1	20021219	US 2002-134781	20020429
PRIORITY APPLN. INFO.:			US 1993-85190	B2 19930630
			US 1995-436799	B2 19950508
			US 1997-921102	A2 19970829
			US 1998-7872	A3 19980115
			US 1998-212178	A 19981215
			WO 1999-US29937	W 19991215
			US 2000-613968	B1 20000711
OTHER SOURCE(S):			MARPAT 133:322036	
GI				



AB Camptothecin derivs. [I; R1, R2 = H, alkyl, alkenyl, benzyl, alkynyl, alkoxy, aryloxy, acyloxy, -OC(O)ORD, {Rd = alkyl, carbamoyloxy, halogen, OH, NO2, CN, N3, CHO, NH2, -SRc (Rc = H, acyl, alkyl, aryl etc.,)}; R3 = H, halogen, NO2, NH2, OH, CN; or R1 + R2 or R2 + R3 together form a group of the formula -O(CH2)nO- wherein n represents the integer 1 or 2; R4 = H, a trialkylsilyl group, F, alkyl, alkenyl, alkynyl, alkoxy; R5 = alkyl, allyl, benzyl, propargyl; R6, R7, R8 = alkyl, alkenyl group, alkynyl, aryl or a -(CH2)nR9 group, wherein n is an integer within the range of 1 through 10 and R9 = OH, alkoxy, amino, alkyl, dialkylamino, halogen, CN, NO2; X = R11, bond; R11 = alkylene, alkenylene] and their pharmaceutically acceptable salts were prepd. as antitumor agents. Thus, [I; R1-R4 = H, XSiR6R7R8 = TMS (II)] was prepd. via reaction of III and Ph isonitrile. II was tested for antitumor activity [IC50 = 3.8 nm vs HL-60 cells; IC50 = 5.6 nm vs. 833K cells; IC50 = 4.2 nm vs DC-3F cells].

IT 264186-80-3P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)


(synthesis and antitumor activity of camptothecin analogs)

RN 264186-80-3 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-[(trimethylsilyl)methyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

10/627,444



IT 275824-64-1P 275824-65-2P


RL: RCT (Reactant); SPN (Synthetic preparation); **PREP**  
(Preparation); RACT (Reactant or reagent)

(synthesis and antitumor activity of camptothecin analogs)

RN 275824-64-1 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,  
9-(acetyloxy)-4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 275824-65-2 CAPLUS

CN Carbamic acid, [(4S)-4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-11-[2-(trimethylsilyl)ethyl]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

10/627,444



IT 203923-89-1P, DB 172 276250-51-2P, DB 174

276250-52-3P, DB 173


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)

(synthesis, stability parameters in different biol. fluids and antitumor activity of camptothecin analogs)

RN 203923-89-1 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4,9-dihydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 276250-51-2 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4,9-dihydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

10/627,444



RN 276250-52-3 CAPLUS  
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,  
9-amino-4-ethyl-11-[2-(trimethylsilyl)ethyl]-, (4S)-(9CI) (CA  
INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2000:421147 CAPLUS  
DOCUMENT NUMBER: 133:43697  
TITLE: Preparation of camptothecin analogs for use as  
antitumor agents  
INVENTOR(S): Curran, Dennis P.; Josien, Hubert; Bom, David; Burke,  
Thomas G.  
PATENT ASSIGNEE(S): University of Pittsburgh, USA  
SOURCE: PCT Int. Appl., 144 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 7  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035924	A1	20000622	WO 1999-US29937	19991215
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				



10/627,444


MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
US 6136978 A 20001024 US 1998-212178 19981215  
EP 1140948 A1 20011010 EP 1999-965287 19991215  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO  
JP 2002532505 T2 20021002 JP 2000-588183 19991215  
PRIORITY APPLN. INFO.: US 1998-212178 A 19981215  
US 1993-85190 B2 19930630  
US 1995-436799 B2 19950508  
US 1997-921102 A2 19970829  
WO 1999-US29937 W 19991215  
OTHER SOURCE(S): MARPAT 133:43697  
GI



- AB Camptothecin analogs I [R1, R2 = H, OH, NO2, CN, N3, CHO, NH2, NHNH2, SH, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, acyloxy, acyl, carbamoyloxy, halogen, acylthio, alkylthio, arylthio, etc.; R3 = H, NO2, NH2, OH, CN, halogen; R2R3 = O(CH2)nO, n = 1, 2; R4 = H, F, alkyl, alkenyl, alkynyl, trialkylsilyl, alkoxy; R5 = allyl, benzyl, propargyl, alkyl; R6 = trialkylsilyl, trialkylsilylalkyl, etc.] were prepd. for use as anticancer agents. Thus, I (R1-4 = H, R5 = Et, R6 = SiMe3) was prepd. starting from (4S)-4-ethyl-4-hydroxy-6-iodo-1H-pyrano[3,4-c]pyridine-3,8(4H,7H)-dione and (3-bromo-1-propynyl)trimethylsilane. The prepd. camptothecin analogs were tested for inhibition of growth of HL-60, 883K, and DC-3F cancer cell lines, for enhancement of topoisomerase I mediated DNA cleavage, and for inhibition of topoisomerase I mediated DNA relaxation.
- IT **275824-64-1P 275824-65-2P**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)  
(prepn. of camptothecin derivs. for use as antitumor agents)
- RN 275824-64-1 CAPLUS
- CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 9-(acetyloxy)-4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/627,444



RN 275824-65-2 CAPLUS

CN Carbamic acid, [(4S)-4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-11-[2-(trimethylsilyl)ethyl]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 203923-89-1P, DB 172 264186-80-3P 276250-51-2P  
, DB 174 276250-52-3P, DB 173


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)  
(prepn. of camptothecin derivs. for use as antitumor agents)

RN 203923-89-1 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/627,444



RN 264186-80-3 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,  
4-ethyl-4-hydroxy-11-[(trimethylsilyl)methyl]-, (4S)- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry. Rotation (+).



RN 276250-51-2 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,  
4-ethyl-4,9-dihydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 276250-52-3 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,

10/627,444

9-amino-4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:568804 CAPLUS

DOCUMENT NUMBER: 129:189517

TITLE: Highly lipophilic camptothecin derivatives

INVENTOR(S): Hausheer, Frederick H.; Haridas, Kochat; Seetharamulu, P.; Reddy, Dasharatha G.; Yao, Shijie; Petluru, Pavankumar N. V.; Murali, Dhanabalan

PATENT ASSIGNEE(S): Bionumerik Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9835940	A1	19980820	WO 1998-US2375	19980211
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9862725	A1	19980908	AU 1998-62725	19980211
EP 1017675	A1	20000712	EP 1998-904990	19980211
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
US 6169080	B1	20010102	US 1998-22310	19980211
JP 2001511807	T2	20010814	JP 1998-535835	19980211
PRIORITY APPLN. INFO.:			US 1997-37148P	P 19970214
			US 1997-37995P	P 19970213
			WO 1998-US2375	W 19980211

OTHER SOURCE(S): MARPAT 129:189517

GI



AB Lipophilic camptothecin derivs. (I) [R1 = C(O)R3, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted aryl, SR4, halo, oxo, S(O)R5, OSO2CF3, substituted silyl; R2 = H, OH, protected OH; R3 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted, halo; R4 = R5 = (un)substituted alkyl; R6 = H, halo, alkyl, NH2, NO2] were prep'd. in the form of the free bases or pharmaceutically acceptable acid addn. salts as highly lipophilic, lactone stable, and do not require metabolic activation, and are used as Topoisomerase I inhibitors to treat patients with cancer. Pharmaceutical formulations (no data) consist of I in soln. or suspension with one or more pharmaceutical excipients or diluents.


IT 203923-89-1P 211917-36-1P 211917-42-9P  
211917-44-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)  
(synthesis of highly lipophilic camptothecin derivs.)

RN 203923-89-1 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,  
4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 211917-36-1 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,  
4-ethyl-4-hydroxy-11-[3-(trimethylsilyl)-2-propenyl]-, (4S)- (9CI) (CA

10/627,444


INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 211917-42-9 CAPLUS  
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,  
4-ethyl-9-fluoro-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



RN 211917-44-1 CAPLUS  
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,  
4-ethyl-10-fluoro-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:147333 CAPLUS

DOCUMENT NUMBER: 128:205022

TITLE: synthesis of highly lipophilic camptothecin derivatives

INVENTOR(S): Hausheer, Frederick Herman; Haridas, Kochat; Seetharamulu, Peddaiahgari; Murali, Dhanabalan; Reddy, Dasharatha Gauravaram; Yao, Shijie; Petluru, Pavankumar

PATENT ASSIGNEE(S): Bionumerik Pharmaceuticals, Inc., USA; Lucas, Brian Ronald; Hausheer, Frederick Herman; Haridas, Kochat; Seetharamulu, Peddaiahgari; Murali, Dhanabalan; Reddy, Dasharatha Gauravaram; Yao, Shijie; Petluru, Pavankumar

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807727	A1	19980226	WO 1997-GB2205	19970815
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9740204	A1	19980306	AU 1997-40204	19970815
AU 718799	B2	20000420		
EP 925301	A1	19990630	EP 1997-937656	19970815
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1227559	A	19990901	CN 1997-197194	19970815
CN 1107678	B	20030507		
BR 9711319	A	20000118	BR 1997-11319	19970815
NZ 334240	A	20000128	NZ 1997-334240	19970815
JP 2000516933	T2	20001219	JP 1998-510497	19970815
US 5910491	A	19990608	US 1997-914207	19970819

10/627,444

US 6028078	A	20000222	US 1998-178780	19981026
US 6194579	B1	20010227	US 1999-470773	19991223
PRIORITY APPLN. INFO.:			US 1996-24171P	P 19960819
			WO 1997-GB2205	W 19970815
			US 1997-914207	A3 19970819
			US 1998-178780	A1 19981026
OTHER SOURCE(S):			MARPAT 128:205022	
GI				




AB Lipophilic camptothecin derivs. (I) [R1 = C(O)R3, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted aryl, SR4, halo, oxo, S(O)R5, OSO2CF3, substituted silyl; R2 = H, OH, protected OH; R3 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted, halo; R4 = R5 = (un)substituted alkyl] were prepd. in the form of the free bases or pharmaceutically acceptable acid addn. salts as highly lipophilic, lactone stable, and do not require metabolic activation, and are anti-neoplastic compds.

IT **203923-89-1P 203923-97-1P**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)  
(synthesis of highly lipophilic camptothecin derivs.)

RN 203923-89-1 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203923-97-1 CAPLUS


CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-[3-(trimethylsilyl)-1-propenyl]-, (S)- (9CI) (CA



10/627,444

INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 09:40:20 ON 10 DEC 2003)

FILE 'REGISTRY' ENTERED AT 09:40:57 ON 10 DEC 2003

L1 STRUCTURE UPLOADED  
L2 0 S L1  
L3 11 S L1 FULL


FILE 'CAPLUS' ENTERED AT 09:42:00 ON 10 DEC 2003

L4 22 S L3  
L5 5 S L3/PREP

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Ak

10/627,444

Structure attributes must be viewed using STN Express query preparation.